Skip to main content
. 2022 Aug 17;14(8):1712. doi: 10.3390/pharmaceutics14081712

Figure 8.

Figure 8

Proposed anticancer mechanism for Bis-PMSs 5 and 6. Decreased activity of IL-6R via IL-6Rβ (gp130) targeting may cause lower levels of activated/phosphorylated STAT3. The decrease in STAT3 activity reduces expression of survival factors and mitochondrial functionality. As a result, cell proliferation is repressed and the mitochondrial apoptotic pathway is activated, respectively. Simultaneously, direct inhibition of mitochondrial metabolism by Bis-PMSs 5 and 6 leads to decreased cell growth and cell death.